Abstract: The disclosure provides methods and compositions for treating glioblastoma (GBM) using a 5T4-targeting agent, e.g., a superantigen conjugate comprising an anti-5T4 antibody.

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

Abstract: The invention provides methods or compositions for treating cancer using a superantigen conjugate in combination with a B-cell depleting agent, e.g., an anti-CD20 antibody.

Abstract: The invention provides methods or compositions for treating cancer using an immune cell, e.g, a T-cell, e.g., a CAR T-cell, optionally in combination with a superantigen conjugate. The invention also provides methods for making immune cells, e.g, T-cells, e.g, CAR T-cells, for use in the treatment of cancer.

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

Abstract: The invention provides methods or compositions for treating cancer using a superantigen conjugate optionally in combination with a PD-1-based inhibitor.

Abstract: Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with a PD-1 inhibitor.

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

Abstract: Provided is a method for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

Abstract: The invention provides methods or compositions for enhancing the potency of a targeted cancer immunotherapy in a subject by using a superantigen in combination with an immunopotentiator (for example, a PD-1 inhibitor).

Abstract: A method for treating a cancer, by determining a patient to have an ECOG (Eastern Cooperative Oncology Group) score of 0 or 1 and selecting that patient for treatment, and administering to the patient an effective amount of an immunomodulating composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: (i) is extracted from bile of animals; (ii) is capable of stimulating monocytes and/or macrophages; (iii) is capable of modulating tumor necrosis factor production and/or release; (iv) contains no measurable level of IL-1?, IL-1?, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-?; (v) is not cytotoxic to human peripheral blood mononuclear cells; and (vi) is not an endotoxin. A method of increasing the survival rate of a cancer patient.

Abstract: A method for treating a cancer, by determining a patient to have an ECOG (Eastern Cooperative Oncology Group) score of 0 or 1 and selecting that patient for treatment, and administering to the patient an effective amount of an immunomodulating composition comprising small molecular weight components of less than 3000 daltons, and having the following properties: (i) is extracted from bile of animals; (ii) is capable of stimulating monocytes and/or macrophages; (iii) is capable of modulating tumor necrosis factor production and/or release; (iv) contains no measurable level of IL-1?, IL-1?, TNF, IL-6, IL-8, IL-4, GM-CSF or IFN-?; (v) is not cytotoxic to human peripheral blood mononuclear cells; and (vi) is not an endotoxin.

Abstract: The invention concerns prodrugs wherein the drug converts from its inactive form to its active form due to catalytic activity of nucleic acid sequences associated with the prodrug.

Abstract: The present invention relates to methods for identifying nucleic acid molecules that localize in the extracellular space, and combining them with known drugs to ultimately enhance the efficacy of existing drugs by simply increasing drug targeting. Other embodiments apply methods whereby an existing drug first is combined with a random population of oligonucleotides, then the resulting chimeric molecules are subjected to iterative rounds of evolution to yield a population of chimeric molecules that is enriched in the species of chimeric molecules that are preferentially excluded from cells. The chimeric molecules of the present invention have superior targeting capabilities than the uncombined drugs.

Abstract: The present invention relates to methods of using oligonucleotides for increasing the efficacy of existing drugs. In some embodiments, oligonucleotides are selected from a random population for their ability to enter cells. Then the selected oligonucleotides are combined with existing drugs to form chimeric-drug oligonucleotide molecules that access cells more readily than the uncombined drugs. Alternatively, the oligonucleotides are combined with the existing drug, and the resulting chimeric molecules are selected for their ability to enter cells. The chimeric drug-olignucleotide molecules are designed to improve various pharmacological properties of existing drugs, including organ and tissue specificity, and drug targeting.

Abstract: The present invention relates to methods of using amino acid sequences for increasing the efficacy of existing drugs. In some embodiments, amino acid sequences are generated and combined with existing drugs to generate drug-amino acid sequence chimeric complexes that have superior pharmacological properties than the uncombined drugs. The chimeric complexes are designed to target only desired organs, without affecting other organs where the drug's activity is not desired, and to enhance drug bioavailability without losing the drugs' therapeutic properties.

Abstract: The present invention concerns a method and kit for carrying out in vitro evolution of a catalytic nucleic acid seuqences in a continuous manner, wherein the evolving nucleic acid sequences are DNA sequences.

Abstract: A method for increasing the specificity of hybridization between a nucleic acid probe and a nucleic acid sequence to be detected, by addition of blocker molecules, which are complementary to the probe, raise of temperature in order to melt non-perfectly matched hybrids of probe and detected nucleic acid sequences, and lowering of the temperature again.

Abstract: A method for detecting the presence of an assayed nucleic acid sequence in a sample is an essentially two stage-procedure. As illustrated, in a first stage the sample is reacted in a manner which gives rise to the production of a triggering oligonucleotide where the sample contains the assayed sequence. In the second stage, the reaction product is incubated under appropriate conditions with an amplification system whereby, in the presence of triggering oligonucleotide, a large amount of a nucleic acid product is obtained. The detection of this product thus indicates the presence of the assayed sequence in the sample.